Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924496 | 0.92 | KMT2A (0.63) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL9347360 | 0.87 | KMT2A (0.59) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL6667000 | 0.81 | TBXAS1 (0.51) | KMT2AMEN1ALDH1A1GAACYP4Z1 | |
| SCHEMBL68851 | 0.81 | CYP4Z1 (0.62) | KMT2AMEN1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL3263213 | 0.80 | TRPV1 (0.56) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL3263209 | 0.80 | TRPV1 (0.56) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL606715 | 0.79 | HTT (0.56) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL28578397 | 0.79 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL21177743 | 0.78 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1GAAKLK7 | |
| SCHEMBL181473 | 0.78 | HPGD (0.61) | ALDH1A1GAACYP4Z1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9403773-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9045464-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642619-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-8269011-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-2152699-B1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2152699-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008150029-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | KMT2A 1903/4885MEN1 4059/4885ALDH1A1 692/4885 |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | KMT2A 1903/4885MEN1 4059/4885ALDH1A1 692/4885 |
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | KMT2A 1903/4885MEN1 4059/4885ALDH1A1 692/4885 |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | KMT2A 1903/4885MEN1 4059/4885ALDH1A1 692/4885 |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | KMT2A 1903/4885MEN1 4059/4885ALDH1A1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.